{"entity":{"id":"nct06393374","kind":"trial","name":"Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)","aka":[],"tldr":"A phase 3 trial of Pembrolizumab, Sacituzumab tirumotecan and Capecitabine in triple-negative breast cancer, run by Merck Sharp & Dohme LLC, now recruiting.","summary":"Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) is a phase 3 interventional study registered as NCT06393374 by Merck Sharp & Dohme LLC, with 1530 participants planned, started 2024-06-24 and due to reach its primary completion in 2030-12-16. Interventions recorded: Pembrolizumab, Sacituzumab tirumotecan and Capecitabine.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06393374","url":"https://clinicaltrials.gov/study/NCT06393374"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab","sacituzumab-tirumotecan","capecitabine"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06393374","phase":"3","setting":"A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surgery","sponsor":"Merck Sharp & Dohme LLC","enrolled":1530,"outcomes":[]},"route":"/trials/nct06393374/","neighbours":{"cancer":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"sacituzumab-tirumotecan","kind":"drug","name":"Sacituzumab tirumotecan","route":"/drugs/sacituzumab-tirumotecan/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}